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A B S T R A C T
Background
Asthma is a condition of the airways affecting more than 300 million adults and children worldwide. National and international
guidelines recommend titrating up the dose of inhaled corticosteroids (ICS) to gain symptom control at the lowest possible dose because
long-term use of higher doses of ICS carries a risk of systemic adverse events. For patients whose asthma symptoms are controlled on
moderate or higher doses of ICS, it may be possible to reduce the dose of ICS without compromising symptom control.
Objectives
To evaluate the evidence for stepping down ICS treatment in adults with well-controlled asthma who are already receiving a moderate
or high dose of ICS.
Search methods
We identified trials from the Specialised Register of the Cochrane Airways Group and conducted a search of ClinicalTrials.gov (
www.ClinicalTrials.gov) and the World Health Organization (WHO) trials portal (www.who.int/ictrp/en/). We searched all databases
from their inception with no restriction on language. We also searched the reference lists of included studies and relevant reviews. We
performed the most recent search in July 2016.
Selection criteria
We included randomised controlled trials (RCTs) of at least 12 weeks’ duration and excluded cross-over trials. We looked for studies of
adults (aged ≥ 18 years) whose asthma had been well controlled for a minimum of three months on at least a moderate dose of ICS.
We excluded studies that enrolled participants with any other respiratory comorbidity.
We included trials comparing a reduction in the dose of ICS versus no change in the dose of ICS in people with well-controlled asthma
who a) were not taking a concomitant long-acting beta agonist (LABA; comparison 1), and b) were taking a concomitant LABA
(comparison 2).
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Data collection and analysis
Two review authors independently screened the search results for included studies, extracted data on prespecified outcomes of interest and
assessed the risk of bias of included studies; we resolved disagreements by discussion with a third review author.We analysed dichotomous
data as odds ratios (ORs) using study participants as the unit of analysis and analysed continuous data as mean differences (MDs). We
used a random-effects model. We rated all outcomes using the GRADE (Grades of Recommendation, Assessment, Development and
Evaluation) system and presented results in ’Summary of findings’ tables.
Main results
We included six studies, which randomised a total of 1654 participants (ICS dose reduction, no concomitant LABA (comparison 1):
n = 892 participants, three RCTs; ICS dose reduction, concomitant LABA (comparison 2): n = 762 participants, three RCTs). All
included studies were RCTs with a parallel design that compared a fixed dose of ICS versus a 50% to 60% reduction in the dose of ICS
in adult participants with well-controlled asthma. The duration of the treatment period ranged from 12 to 52 weeks (mean duration
21 weeks; median duration 14 weeks). Two studies were performed in the setting of primary care, two were performed in the secondary
care setting and two reported no information on setting.
Meta-analysis was hampered by the small number of studies contributing to each comparison, combined with heterogeneity among
outcomes reported in the included studies. We found the quality of synthesised evidence to be low or very low for most outcomes
considered because of a risk of bias (principally, selective reporting), imprecision and indirectness. Although we found no statistically
significant or clinically relevant differences between groups with respect to any of the primary or secondary outcomes considered in
this review, the data were insufficient to rule out benefit or harm.
Authors’ conclusions
The strength of the evidence is not sufficient to determine whether stepping down the dose of ICS is of net benefit (in terms of fewer
adverse effects) or harm (in terms of reduced effectiveness of treatment) for adult patients with well-controlled asthma. A small number
of relevant studies and varied outcome measures limited the number of meta-analyses that we could perform. Additional well-designed
RCTs of longer duration are needed to inform clinical practice regarding use of a ’stepping down ICS’ strategy for patients with well-
controlled asthma.
P L A I N L A N G U A G E S U M M A R Y
Stepping down the dose of inhaled corticosteroids for adults with asthma
Background
Asthma is a condition of the airways affecting more than 300 million adults and children worldwide. National and international
guidelines recommend increasing the dose of inhaled corticosteroids (ICS) in steps to gain control of symptoms at the lowest possible
dose because long-term use of higher doses of ICS carries a risk of side effects. For patients whose asthma symptoms are controlled on
moderate or higher doses of ICS, it may be possible to reduce the dose of ICS (step down) without losing control of asthma symptoms.
Review question
We searched for studies (minimum length 12 weeks) in people with well-controlled asthma that compared the effect of reducing the
dose of ICS versus maintaining the dose of ICS. Studies had to include adults aged 18 years or older whose asthma was well controlled
on a medium dose of ICS for a minimum of three months. We were also interested in determining whether taking another type of
inhaled asthma medication (long-acting beta agonists - LABAs) would influence the results. Two review authors screened the search
results independently of each other and determined which studies were relevant for inclusion in this review. The relevant information
from these studies was also added to this review by two review authors independently.
Results
We found six studies that were relevant to our review. Overall, we found no differences between groups (reduced ICS dose vs maintained
ICS dose) in terms of asthma attacks, asthma control, quality of life or side effects. Taking or not taking LABA at the same time did not
appear to affect the results. However, we assessed the quality of the evidence as low or very low because of the low number of studies
found and problems with how the studies were reported. This means that we cannot be certain of our findings; additional studies are
needed to explore this topic.
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Conclusions
In conclusion, current evidence is not good enough to show whether patients can reduce their ICS dose without losing control of their
asthma. It is also not clear whether stepping down the dose of ICS would reduce the occurrence of side effects. Additional studies are
needed to answer this question.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
ICS dose reduction compared with no change in ICS dose (no concomitant LABA) for adults with asthma
Patient or population: adults with asthma
Setting: primary care and specialist centres
Intervention: ICS dose reduct ion
Comparison: no change in ICS dose (no concomitant LABA)
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aThe quality of the evidence was downgraded once for indirectness (included studies were performed at specialist centres) and twice for imprecision (no events reported by
Magnussen 2000; conf idence intervals include null ef fect and appreciable benef it or harm)
bThe quality of the evidence was downgraded once for risk of bias (select ive report ing) and once for indirectness (single study representat ive of one sett ing and drug regimen)
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OCS, oral cort icosteroid; OR, odds rat io; RCT, randomised controlled trial; RR, risk rat io; SAE, serious adverse event
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to the est imate of ef fect.
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of ef fect but may be substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of ef fect.







































































































B A C K G R O U N D
Description of the condition
Asthma is a condition of the airways affecting adults and chil-
dren. The number of diagnoses worldwide is estimated at more
than 300million (Global AsthmaNetwork 2014; Partridge 2006).
During an asthma attack (exacerbation), narrowing of the airways
and excess mucus production occurs, causing symptoms of chest
tightness, wheezing and breathlessness. Lung function tests typi-
cally show airflow obstruction with a low peak expiratory flow rate
(PEFR), low forced expiratory volume in one second (FEV1) and
a low FEV1/forced vital capacity (FVC) ratio (SIGN/BTS 2016).
Lung function abnormalities improve and function may return to
normal with treatment. Variability in measures of airflow is the
hallmark of asthma.
Exacerbations of asthma can be triggered by environmental stim-
uli. In immunoglobulin E (IgE)-mediated asthma (which may
account for half of asthma cases) (Pearce 1999), indoor inhaled
allergens such as house dust mite, cat and dog are often impli-
cated (Custovic 2012). Other recognised environmental stimuli
include air pollutants such as ozone and fine particulates, active
and passive exposure to tobacco smoke (Xepapadaki 2009), in-
dustrial chemicals such as phthalates (Jaakkola 2008), isocyanates
(Fisseler-Eckhoff 2011), viral infections and cold air.
Description of the intervention
Acute episodes of asthma are treated with reliever therapy, usu-
ally a short-acting beta2-agonist (SABA). Inhaled corticosteroids
(ICS) are used widely as first-line therapy for patients with asthma
that is uncontrolled on reliever therapy alone (SIGN/BTS 2016).
Inhaled corticosteroids, which effectively relieve symptoms and
prevent asthma exacerbations (Adams 2005; Adams 2008), are
preferable to treatment by the oral route, as they lead to lower
systemic absorption and fewer side effects. However, economic
and social factors may contribute to non-compliance with inhaler-
based therapies in some low- andmiddle-income countries (GINA
2016). A variety of devices are available for delivery of ICS at
differing doses and particle sizes. Generally, ICS are taken twice
daily, although some newer preparations are taken once daily. For
patients with persistent asthma, ICS are often taken alongside a
long-acting beta2 agonist (LABA), sometimes via a combination
inhaler. ICS should be commenced at a dose appropriate to dis-
ease severity and control. National and international guidelines
recommend titrating up the dose of ICS to gain symptom control
at the lowest possible dose. Long-term use of higher doses of ICS
carries risk of systemic adverse events (i.e. side effects caused by
the action of the steroid at sites other than the intended target -
the airways) (Lipworth 1999); however, lower doses of up to 800
mcg per day of beclomethasone dipropionate are considered tol-
erable (SIGN/BTS 2016). For patients whose asthma symptoms
are controlled on moderate or higher doses of ICS, it may be pos-
sible to reduce the dose of ICS without compromising symptom
control (Hawkins 2003).
How the intervention might work
ICS offer effective treatment for asthma owing to their anti-in-
flammatory and decongestive effects on bronchial airways (Tse
1984). LABA function by decreasing bronchial hyperreactivity to
physical and chemical stimuli and by relaxing bronchial smooth
muscle (Lipworth 1992). Guidelines for asthma treatment fo-
cus on achieving, then maintaining, control while balancing the
risks associatedwith long-termmedication (Bateman 2008).Once
asthma control is achieved (e.g. as per GINA 2016 criteria), guide-
lines recommend ’stepping down’ treatment to the lowest possi-
ble dose of ICS (SIGN/BTS 2016). These recommendations are
based on known risks of systemic adverse effects (e.g. loss of bone
density in adults, growth retardation in children) associated with
long-term use of high-dose ICS (Colice 2006; Lipworth 1999;
SIGN/BTS 2016).
Why it is important to do this review
Patients with persistent asthma are generally treated with a high
dose of ICS or with a combination of ICS and LABA (Ducharme
2010). Two separate Cochrane reviews (Ahmad 2015; Kew 2015)
have synthesised the evidence for removing the LABA from the
ICS/LABA combination when treating children and adults with
asthma. Stepping down the dose of ICS may reduce the likeli-
hood of unwanted side effects, particularly the systemic side effects
of steroid use (Colice 2006; SIGN/BTS 2016). Indeed, current
British Thoracic Society (BTS)/Scottish Intercollegiate Guide-
lines Network (SIGN) guidelines recommend that ICS should be
titrated to the lowest possible dose at which effective asthma con-
trol is maintained (SIGN/BTS 2016). However, debate continues
regarding the best protocol for stepping down ICS treatment, par-
ticularly with respect to the lowest acceptable dose of ICS and the
rate of down-titration (Rogers 2012). Therefore, synthesis of the
evidence for ’stepping down ICS therapy’ is important. Finally,
ICS are among themost widely prescribed repeat medications and
thus account for a substantial proportion of drug spending in the
United Kingdom and in other countries (NHS 2013). Any strat-
egy to reduce the use of ICSmay thus represent an important cost-
saving measure.
O B J E C T I V E S
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Toevaluate the evidence for steppingdown ICS treatment in adults
with well-controlled asthma who are already receiving a moderate
or high dose of ICS.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included parallel-group randomised controlled trials (RCTs)
of at least 12 weeks’ duration. We included studies reported as full
text, those published as abstract only and unpublished data. We
did not exclude studies on the basis of language or blinding.
Types of participants
We included adults (aged≥ 18 years) whose asthma was well con-
trolled for a minimum of three months on at least a moderate dose
of ICS (i.e. a dose of at least 400mcgbeclomethasone dipropionate
(BDP) or equivalent) (SIGN/BTS 2016). We classified asthma
control according to predefined criteria, for example, as per the
criteria described in GINA 2016 (i.e. daily symptoms twice or less
often per week, use of rescue inhaler twice or less often per week,
no nocturnal symptoms and no limitation to daily activities), or
as per the asthma control questionnaire (i.e. a score less than 1.5).
We excluded participants who had the following comorbidities/
characteristics: chronic obstructive pulmonary disease (COPD),
bronchiectasis or any other respiratory comorbidity.
If studies enrolled adults and adolescents (aged 10 to 17 years)
(WHO 2014), and data were not reported separately, we included
the study if the mean age of participants in the intervention and
comparator groups was 18 years or older.
Types of interventions
We included trials that compared the following.
1. Reduction in the dose of ICS versus no change in the dose
of ICS, in people with asthma whose condition was well
controlled on at least a moderate dose of any ICS, but who were
not taking a concomitant LABA.
2. Reduction in the dose of ICS versus no change in the dose
of ICS, in people with asthma whose condition was well
controlled on at least a moderate dose of any ICS and who were
taking a concomitant LABA.
For both comparisons, a different ICS could be used in the inter-
vention and comparator groups, provided both groups used the
same beclomethasone dipropionate (BDP) equivalent dose of ICS
(≥ 400 mcg) before randomisation. We excluded studies in which
treatment with ICS was stopped, as this relates to a different clin-
ical question. We included studies that permitted use of short-
acting reliever medications, provided they were not part of the
randomised treatment.
For the latter comparison (patients taking a concomitant LABA),
several studies included participants who used combination (ICS/
LABA) inhalers; we excluded studies in which randomised treat-
ment included a concurrent dose reduction of both ICS and
LABA, because this strategy relates to a different clinical question.
We also excluded studies if randomised treatment involved a step-
down to single inhaler therapy (i.e. ’single inhaler maintenance
and reliever therapy’ (SMART)) with a lower dose of ICS, because
this also relates to a different clinical question that is addressed in
another review (Kew 2013).
Types of outcome measures
Primary outcomes
1. Exacerbations requiring oral corticosteroids
2. Asthma control (measured on a validated scale; preferred
measure is the Asthma Control Questionnaire (ACQ) score)
3. All-cause serious adverse events
4. Steroid-related adverse events
Secondary outcomes
1. Health-related quality of life (measured on a validated scale;
preferred measure is the Asthma Quality of Life Questionnaire
(AQLQ) score)
2. Lung function indices (preferred measure is trough FEV1)
3. Exacerbations requiring hospitalisation
4. Exacerbations requiring an emergency department visit
5. Mortality
Reporting one or more of these outcomes in a trial was not an
inclusion criterion.
Search methods for identification of studies
Electronic searches
We identified trials from the Cochrane Airways Group Specialised
Register (CAGR), which is maintained by the Group’s Trials
Search Co-ordinator. The Register contains trial reports identified
through systematic searches of bibliographic databases including
the Cochrane Central Register of Controlled Trials (CENTRAL),
MEDLINE, Embase, the Cumulative Index to Nursing and Al-
lied Health Literature (CINAHL), the Allied and Complemen-
tary Medicine Database (AMED) and PsycINFO, and via hand-
searches of respiratory journals and meeting abstracts (Appendix
1). We searched all records in the Cochrane Airways Group Spe-
cialised Register using the search strategy presented in Appendix
2.
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We also conducted
a search of ClinicalTrials.gov (https://clinicaltrials.gov/) and the
World Health Organization (WHO) International Clinical Trials
Registry Platform (ICTRP) Search Portal (http://apps.who.int/
trialsearch/).We searched all databases from their inception to July
2016, and we imposed no restriction on language of publication.
Searching other resources
We checked the reference lists of all primary studies and review
articles for additional references. We searched relevant manufac-
turers’ websites for trial information.
On 4 October 2016, we searched for errata and retractions from
included studies published in full text on PubMed.
Data collection and analysis
Selection of studies
Two review authors (DE, NH) independently screened titles and
abstracts for inclusion of all potential studies identified as a result
of the search and coded them as ’retrieve’ (eligible or potentially
eligible/unclear) or ’do not retrieve’. Two review authors (DE, NH
or IC) independently retrieved and screened the full-text reports/
publications to identify studies for inclusion, and to identify and
record reasons for exclusion of ineligible studies. We resolved dis-
agreements through discussion, or, if required, we consulted a
third review author (PM). We identified and excluded duplicates
and collated multiple reports of the same study, so that each study
rather than each report was the unit of interest in the review. We
recorded the selection process in sufficient detail to complete a
Preferred Reporting Items for Systematic Reviews andMeta-Anal-
yses (PRISMA) flow diagram and the Characteristics of excluded
studies table.
Data extraction and management
We used a data collection form to collect information on study
characteristics and outcome data after piloting the form on at least
one study included in the review. Two review authors (DE, NH)
extracted the following study characteristics from included studies
in duplicate.
1. Methods: study design, total duration of study, details of
any ’run-in’ period, number of study centres and locations, study
setting, withdrawals, dates of study.
2. Participants: N, mean age, age range, gender, severity of
condition, diagnostic criteria, baseline lung function, smoking
history, inclusion criteria and exclusion criteria and details of
criteria for stepping down treatment (clinical, e.g. symptoms,
lung function, exacerbation history; airway responsiveness, e.g.
mannitol challenge; inflammatory biomarkers, e.g. exhaled nitric
oxide).
3. Interventions: intervention, comparison, concomitant
medications, excluded medications.
4. Outcomes: primary and secondary outcomes specified and
collected, time points reported.
5. Notes: funding for trial, notable conflicts of interest of trial
authors.
Two review authors (IC, DE) independently extracted outcome
data from included studies. We noted in the Characteristics of
included studies table if outcome data were not reported in a
useable way. We resolved disagreements by reaching consensus
or by involving a third review author (PM). One review author
(DE) transferred data into Cochrane’s statistical software, Review
Manager 2014. We double-checked that data were entered cor-
rectly by comparing data presented in the systematic review against
study reports. A second review author (NH) spot-checked study
characteristics for accuracy against the trial report.
Assessment of risk of bias in included studies
Two review authors (DE, PM) independently assessed risk of bias
for each study using Cochrane’s tool for assessing risk of bias (
Higgins 2011). We resolved disagreements by discussion or by
consultation with another review author (IC or NH).
We assessed risk of bias according to the following domains.
1. Random sequence generation.
2. Allocation concealment.
3. Blinding of participants and personnel.
4. Blinding of outcome assessment.
5. Incomplete outcome data.
6. Selective outcome reporting.
7. Other bias.
We graded each potential source of bias as high, low or unclear
and provided a quote from the study report together with a justifi-
cation for our judgement in a ’Risk of bias table’. We summarised
risk of bias judgements across different studies for each of the do-
mains listed. We considered blinding separately for different key
outcomes when necessary (e.g. for unblinded outcome assessment,
risk of bias for all-cause mortality may be very different from that
observed for a patient-reported pain scale). When information on
risk of bias was related to unpublished data or correspondence
with a trialist, we noted this in the ’Risk of bias table’.
When considering treatment effects, we took into account the risk
of bias for studies that contributed to that outcome.
Assesment of bias in conducting the systematic
review
We conducted the review according to this published protocol
and reported any deviations from it in the Differences between
protocol and review section of the systematic review.
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Measures of treatment effect
We analysed dichotomous data as odds ratios (ORs), and continu-
ous data as mean differences (MDs). We entered data presented as
a scale with a consistent direction of effect.When included studies
reported dichotomous data as risk ratios (RRs) or hazard ratios
(HRs), we calculated and presented the ORs.
We undertook meta-analyses only when this was meaningful (i.e.
when treatments, participants and the underlying clinical question
were similar enough for pooling to make sense).
We narratively described skewed data reported as medians and
interquartile ranges.
When multiple trial arms were reported in a single trial, we in-
cluded only the relevant arms. If two comparisons (e.g. drug A vs
placebo and drug B vs placebo) were combined in the same meta-
analysis, we halved the control group to avoid double-counting.
When the duration of studies included in an analysis varied by
more than three months, we performed sensitivity analyses to ex-
amine whether study duration influenced the treatment effect. If
an influence of study duration was apparent, we re-expressed ORs
as a variety of numbers needed to treat (NNTs) across a range
of assumed control risks (control group risks are likely to vary in
studies of different duration) (Higgins 2011).
Unit of analysis issues
For dichotomous outcomes, we used participants, rather than
events, as the unit of analysis (i.e. the number of participants ad-
mitted to hospital at least once rather than the number of admis-
sions per participant). We planned to also analyse exacerbations
leading to admission or to a course of oral steroids as rate ratios
and time to event data, if these data were presented.
Dealing with missing data
We contacted investigators or study sponsors to verify key study
characteristics and to obtain missing numerical outcome data
when possible (e.g. when a study was identified as “abstract only”).
When this was not possible, and missing data were thought to
introduce serious bias, we explored the impact of including such
studies in the overall assessment of results by performing a sensi-
tivity analysis.
Assessment of heterogeneity
We used the I2 statistic to measure heterogeneity among the trials
in each analysis. If we identified substantial heterogeneity (i.e. I2≥
50%), we reported this and explored possible causes by performing
prespecified subgroup analysis.
Assessment of reporting biases
As we included only six studies, we were not able to pool more
than 10 trials to create a funnel plot to explore possible small study
and publication biases.
Data synthesis
We used a random-effects model and planned to perform a sensi-
tivity analysis using a fixed-effect model.
’Summary of findings’ table
We created a ’Summary of findings’ table using all of the out-
comes listed above (Types of outcome measures), with the excep-
tion of mortality and exacerbations requiring an emergency de-
partment visit.Weused the fiveGrading of Recommendations As-
sessment, Development and Evaluation (GRADE) considerations
(study limitations, consistency of effect, imprecision, indirectness
and publication bias) to assess the quality of a body of evidence as
it relates to studies that contributed data to the meta-analyses for
prespecified outcomes. We used methods and recommendations
described in the Cochrane Handbook for Systematic Reviews of In-
terventions and GRADEpro (GRADEproGDT) software (http:/
/www.guidelinedevelopment.org/). We justified all decisions to
downgrade or upgrade the quality of studies by using footnotes,
and we made comments to aid readers’ understanding of the re-
view when necessary.
Subgroup analysis and investigation of heterogeneity
We planned to carry out the following subgroup analyses.
1. Rate of dose reduction (e.g. 25% dose reduction vs 50%
dose reduction).
2. Separate inhaler therapy versus combination inhaler therapy
(i.e. ICS/LABA).
We planned to use the following primary outcomes in subgroup
analyses.
1. Exacerbations requiring oral corticosteroids.
2. Asthma control.
We used the formal test for subgroup interactions provided in
Review Manager 2014.
Sensitivity analysis
We planned to carry out the following sensitivity analyses.
1. Unpublished data (i.e. no peer-reviewed full-text
publication available).
2. Studies at unclear or high risk of bias for blinding.
3. Fixed-effect versus random-effects models.
4. Duration of included studies (e.g. short term (less than
three months) vs longer term (more than three months)).
5. Studies at high risk of any other bias versus those at low risk
of any other bias.
R E S U L T S
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Description of studies
TheCharacteristics of included studies table presents details of the
included studies. We reported in the Characteristics of excluded
studies table reasons for exclusion of studies considered during
review of full-text articles.
Results of the search
We identified 983 records by performing electronic searches of
bibliographic databases and an additional 53 records by searching
clinicaltrials.gov. Of a total of 1034 records (two duplicates re-
moved), we excluded most (n = 972) upon screening titles and ab-
stracts. We examined full-text articles of the remaining 62 records
and excluded 53 records (reporting 41 studies), primarily because
the intervention did not meet the criteria for inclusion in this re-
view (n = 27 studies). The interventions considered were typically
complex and difficult to separate from other components; this re-
sulted in a high rate of exclusions at full-text review stage. Other
reasons for exclusion at this stage included ’wrong study design’ (n
= 8), ’wrong comparator’ (n = 3), ’wrong route of administration’
(n = 2) and ’wrong patient population’ (n = 1). The remaining 11
records reported the findings of six studies, which we included in
this review. Figure 1 depicts the flow of information through the
different stages of this systematic review.
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Figure 1. Study flow diagram.
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Included studies
Six studies met the inclusion criteria and contributed data to
the analyses (Godard 2008; Gunn 1997; Hawkins 2003; Juniper
1991; Knox 2007; Magnussen 2000). The six included studies
randomised a total of 1654 participants (ICS dose reduction, no
concomitant LABA: n = 892; ICS dose reduction, concomitant
LABA: n = 762). The largest (Gunn 1997) and smallest (Juniper
1991) studies included 631 and 28 participants, respectively. All
included studies were reported as full peer-reviewed articles.
Methods
All included studies were RCTs with a parallel design that com-
pared a fixed dose of ICS versus a reduced dose of ICS. Two stud-
ies included three arms (Godard 2008; Gunn 1997), and in one
of these, only two out of three arms were relevant to this review
(Godard 2008). Five studies were performed as double-blind, and
one study was open-label (Gunn 1997). Five studies reported a
run-in period (duration two to eight weeks), and one study was
an extension of a previous 12-month study (Juniper 1991). Du-
ration of the treatment period ranged from 12 to 52 weeks (mean
duration 21 weeks; median duration 14 weeks). Outcome data
were reported at the last time point reported for each study. Most
studies were performed in Europe (Godard 2008; Gunn 1997;
Hawkins 2003; Knox 2007; Magnussen 2000), and one study in
Canada (Juniper 1991). Two studies were conducted in the set-
ting of primary care (Gunn 1997; Hawkins 2003), two were con-
ducted in the secondary care setting (Juniper 1991; Magnussen
2000) and two reported no information on setting (Godard 2008;
Knox 2007).
Participants
We included studies that recruited adult participants aged ≥ 18
years or in which most participants were adults. When reported,
the age range of participants across included studies was 16.2
to 86 years (Godard 2008; Gunn 1997; Hawkins 2003; Knox
2007); in the two studies for which the age range was not reported,
the mean age of participants was approximately 40 years (Juniper
1991; Magnussen 2000). Participants in the included studies had
asthma that was generally well controlled by regular preventive
therapy (i.e. step 2of theBTS/SIGNguidelines; SIGN/BTS 2016)
(Gunn 1997; Juniper 1991; Knox 2007; Magnussen 2000), with
the use of high-dose ICS (≥ 1000 µg BDP) (Hawkins 2003)
or with an add-on therapy (i.e. step 3 of the BTS/SIGN guide-
lines) (Godard 2008). When reported, most participants were
non-smokers (Godard 2008; Hawkins 2003; Knox 2007).
Interventions
All included studies compared a 50% to 60% reduction in dose of
ICS versus no change in ICS dose. In terms of the type and baseline
dose of ICS, studies included a variety of comparisons: fluticasone
propionate (FP) 250µg twice daily versus ciclesonide 160µg once
daily (representing a 50% reduction according to Global Initiative
for Asthma (GINA) guidelines) (Knox 2007); a 50% reduction
in dose of any ICS (as used before the study) (Hawkins 2003);
salmeterol/fluticasone combination (SFC) 50/100 µg twice daily
versus no change (SFC 50/250 µg twice daily) (Godard 2008); a
50% reduction in dose of budesonide versus no change in budes-
onide dose (any dose) (Juniper 1991); and chlorofluorocarbon be-
clomethasone 1000µg/day versus hydrofluoroalkane beclometha-
sone 400µg/day (<50%reduction) (Magnussen 2000). The study
comparison reported by Gunn and colleagues (Gunn 1997) was
as follows: Participants on an initial high dose of ICS (budesonide
400 µg twice daily or beclomethasone 400 µg twice daily or be-
clomethasone 500 µg twice daily delivered via a pressurised me-
tered-dose inhaler (pMDI) and spacer device) were randomised to
receive budesonide 200 µg twice daily via a Turbohaler, or 400 µg
once daily (i.e. both groups represent a halving of the initial ICS
dose). Participants on an initial low dose of ICS (budesonide or
beclomethasone 200 µg twice daily) were randomised to receive
budesonide 100 µg twice daily via a Turbuhaler, or 200 µg once
daily (i.e. both groups represent a halving of the initial ICS dose).
There was no change in initial dose of budesonide or beclometha-
sone in the control group (Gunn 1997).
Inhaler devices varied across studies but were consistent between
intervention and control groups in at least three of the six included
studies. One study used a Diskus dry powder inhaler (Godard
2008); another used the Autohaler, a breath-actuated metered-
dose inhaler (MDI) (Magnussen 2000); one study used a hydroflu-
oroalkane MDI (Knox 2007); another did not report the device
used (Juniper 1991); one study permitted the use of an MDI or a
dry powder inhaler as long as the same device was used through-
out the study (Hawkins 2003); and another used the Turbohaler
for participants in the intervention group and an MDI for those
in the comparator group (Gunn 1997) and considered the two
inhaler types to be equivalent for a given dose.
Outcomes
Outcomes reported were inconsistent across included studies. All
studies reported data on asthma control, although several studies
used scales that were not validated and thus did not contribute data
to themeta-analysis.Most studies reported exacerbations requiring
oral corticosteroids (OCS) (Godard 2008; Hawkins 2003; Knox
2007; Magnussen 2000), all-cause serious adverse events (SAEs)
(Godard 2008; Gunn 1997;Hawkins 2003; Knox 2007) and lung
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function (Godard 2008; Gunn 1997; Juniper 1991; Knox 2007;
Magnussen 2000), although reported measures of lung function
varied across studies. Two studies reported quality of life (QoL):
One study used both the Juniper Asthma QoL Questionnaire and
theDupuy Psychological GeneralWell Being Index (Gunn 1997),
and the second study used the EuroQoL questionnaire and the St
George’s Respiratory Questionnaire (Hawkins 2003). Steroid re-
latedAEs and exacerbations requiring hospitalisation were each re-
ported by two studies (Knox 2007 and Magnussen 2000; Godard
2008 and Hawkins 2003, respectively). Mortality and exacerba-
tions requiring an emergency department visit were each reported
by one study (Godard 2008 and Hawkins 2003, respectively).
Excluded studies
We excluded 53 references (related to 41 studies) following assess-
ment of full-text articles (Characteristics of excluded studies). We
excluded 27 studies as they used an intervention that was not rele-
vant to this review (e.g. a dose reduction of ICS was not used, or a
concomitant reduction in ICS and LABA was used). Eight studies
were excluded because they used a study design not appropriate
for this review (e.g. cross-over or non-randomised design). We ex-
cluded six studies because they used a comparator not relevant to
this review (n = 3; e.g. a dose reduction in the control group) or a
route of administration not relevant to this review was used (n =
2; e.g. the intervention was OCS, not ICS) or because the patient
population studied was not relevant (n = 1; e.g. participants were
children).
Risk of bias in included studies
Please refer to the Characteristics of included studies tables for
details on risk of bias and for supporting evidence for each study.
Figure 2 provides a summary of risk of bias judgements, presented
by study and domain (sequence generation, allocation conceal-
ment, blinding, incomplete data, selective reporting and ’other’).
Figure 3 depicts the risk of bias for each domain, presented as
percentages across all included studies.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
Most studies (five of six) provided insufficient information regard-
ing methods of random sequence generation and concealment of
treatment allocation to allow a judgement on risk of bias (Godard
2008; Gunn 1997; Juniper 1991; Knox 2007; Magnussen 2000);
therefore, the risk of bias for these studies was unclear. One study
(Hawkins 2003) used a computer-generated randomisation se-
quence and concealed allocation method, and was considered to
be at low risk for selection bias.
Blinding
We considered five of six studies (Godard 2008; Hawkins 2003;
Juniper 1991; Knox 2007; Magnussen 2000) to have low risk of
performance and detection bias, as participants, personnel and
outcome assessors were blinded to treatment allocation through
adequate methods. One study (Gunn 1997) used an open-label
design, in which participants, personnel and outcome assessors
were not blinded to treatment allocation; we considered this study
to be at high risk of both performance and detection bias.
Incomplete outcome data
We considered all studies to be at low risk of attrition bias on the
basis of low and balanced rates of participant withdrawal, which
were adequately documented in the trial report.
Selective reporting
We judgedfive studies (Godard 2008;Gunn 1997;Hawkins 2003;
Juniper 1991; Magnussen 2000) to be at high risk of reporting
bias because no study protocol was available and there appeared
to be either non-standard presentation of the data or selective
reporting of data thatwere likely recorded.One study (Knox 2007)
appeared to report a fairly comprehensive set of outcomes (i.e.
exacerbations, steroid-related AEs, all-cause SAEs, lung function
and asthma control); however, a protocol was not available, so we
judged the risk of bias as unclear.
Other potential sources of bias
We judged four studies to be at low risk of other bias, as no other
concerns were identified (Hawkins 2003; Juniper 1991; Knox
2007; Magnussen 2000). We considered Godard 2008 to be at
high risk of other bias because, contrary to the methods described,
investigators randomised a relatively high proportion of partici-
pants who had asthma that was not well controlled and included
them in the full analysis set. We judged Gunn 1997 to be at un-
clear risk of bias because there appeared to be some changes in
the inhaler used to deliver the ICS at the same time as changes in
dose, although we noted that the two inhaler types were consid-
ered equivalent for a given dose.
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Effects of interventions
See: Summary of findings for the main comparison ICS dose
reduction compared with no change in ICS dose (no concomitant
LABA) for adults with asthma; Summary of findings 2 ICS dose
reduction compared with no change in ICS dose (concomitant
LABA) for adults with asthma
Structure of the analysis
As per the protocol, we chose to analyse participants who were
receiving a concomitant LABA separately from those who were
not receiving a concomitant LABA.
Structure of the meta-analysis
We created two main comparison headings within the analysis
tree. For each comparison, we elected to perform a meta-analysis
only when interventions and outcomes were sufficiently similar
for pooling of the data.
Participants not taking concomitant a LABA: ICS
reduction versus no change in ICS dose
This comparison comprised all studies that compared a reduction
in the dose of ICS versus no change in ICS dose among partici-
pantsnot taking a concomitant LABA (Gunn 1997; Knox 2007;
Magnussen 2000).
Participants taking a concomitant LABA: ICS
reduction versus no change in ICS dose
This comparison comprised all studies that compared a reduction
in the dose of ICS versus no change in ICS dose among partici-
pants taking a concomitant LABA (Godard 2008; Hawkins 2003;
Juniper 1991)
Structure of the narrative synthesis
In the following sections, we present a narrative summary of study
results according to the prespecified outcomes. We present pri-
mary outcomes (exacerbations requiring OCS, asthma control,
all-cause SAEs, steroid-related AEs) followed by secondary out-
comes (health-related QoL, lung function, exacerbations requir-
ing hospitalisation, exacerbations requiring an emergency depart-
ment visit, mortality). For each outcome, we describe the effect
of the intervention among participants not taking a concomitant
LABA followed by the effect of the intervention among partici-
pants taking a LABA.
Primary outcomes
Exacerbations requiring oral corticosteroids
ICS stepdown, no concomitant LABA
Stepping down the dose of ICS resulted in no clear benefit or
harm with respect to exacerbations requiring treatment with oral
steroids (odds ratio (OR) 1.86, 95% confidence interval (CI) 0.16
to 21.09; n = 261 participants, two studies; I2 = 0%; Analysis 1.1;
Figure 4). For people who stepped down their dose of ICS, we es-
timated that six more people per 1000 would have an exacerbation
requiring oral steroids, but the confidence intervals ranged from
seven fewer to 132 more people per 1000. We rated the quality of
the evidence as very low after downgrading twice for imprecision
(no events were reported by one of the contributing studies, and
confidence intervals include the null effect (risk ratio (RR) 1.0)
and appreciable benefit (RR 0.75) or harm (RR 1.25)) and once
for indirectness, as the evidence was based on studies operating
out of specialist centres.
Figure 4. Forest plot of comparison: 1 ICS dose reduction versus no change in ICS dose (no concomitant
LABA), outcome: 1.1 Exacerbation requiring OCS.
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ICS stepdown, concomitant LABA
Stepping down the dose of ICS resulted in no clear benefit or
harm with respect to exacerbations requiring treatment with oral
steroids (OR 1.31, 95% CI 0.82 to 2.08; n = 569 participants;
two studies; I2 = 0%; Analysis 2.1; Figure 5). For people who
stepped down their dose of ICS (versus those with no change in
ICS dose), we estimated that 38 more people per 1000 would
have an exacerbation requiring oral steroids, but the confidence
intervals ranged from 23 fewer to 118 more people per 1000.
We rated the quality of the evidence as low after downgrading
once for risk of bias (selective reporting) and once for imprecision
(confidence intervals include null effect and appreciable benefit
(RR 0.75) or harm (RR 1.25)).
Figure 5. Forest plot of comparison: 2 ICS dose reduction versus no change in ICS dose (concomitant
LABA), outcome: 2.1 Exacerbation requiring OCS.
Asthma control
ICS stepdown, no concomitant LABA
Stepping down the dose of ICS resulted in no clear benefit or harm
with respect to asthma control (mean difference (MD) -0.22, 95%
CI -1.05 to 0.61; n = 150 participants; one study; Analysis 1.2).
We rated the quality of the evidence as low after downgrading
once for risk of bias (selective reporting) and once for indirectness
(single study representative of a single setting and drug regimen).
ICS stepdown, concomitant LABA
Stepping down the dose of ICS resulted in no clear benefit or harm
with respect to asthma control as measured by the short asthma
morbidity score (change from baseline: MD 0.16, 95% CI -0.34
to 0.66; n = 242 participants; one study; scale 0 (perfect control)
to 8 (very poor control); Analysis 2.2). We rated the quality of the
evidence as low after downgrading once for risk of bias (selective
reporting) and once for indirectness (single study representative
of a single setting and drug regimen). Nor did stepping down the
dose of ICS result in clear benefit or harm with respect to asthma
control as measured by the Asthma Severity Questionnaire (MD
1.13, 95% CI -0.24 to 2.49; scale 0 (best control) to 6 (worst
control); Analysis 2.3).We rated the quality of the evidence as very
low after downgrading once for risk of bias (selective reporting),
once for indirectness (single study representative of a single setting
and drug regimen) and once for imprecision (confidence intervals
include the null effect (MD 0) and appreciable harm (MD 1.5)).
All-cause SAEs
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ICS stepdown, no concomitant LABA
Stepping down the dose of ICS resulted in no clear benefit or harm
with respect to SAEs (OR 1.24, 95% CI 0.25 to 6.25; n = 742
participants; two studies; I2 = 5%; Analysis 1.3; Figure 6). For
people who stepped down their dose of ICS (versus those with no
change in ICS dose), we estimated that 1 more person per 1000
would have an SAE, but confidence intervals ranged from six fewer
to 37 more people per 1000. We rated the quality of the evidence
as low after downgrading once for risk of bias (selective reporting)
and once for imprecision (confidence intervals include the null
effect and appreciable benefit (RR 0.75) or harm (RR 1.25)).
Figure 6. Forest plot of comparison: 1 ICS dose reduction versus no change in ICS dose (no concomitant
LABA), outcome: 1.3 All-cause SAEs.
ICS stepdown, concomitant LABA
Stepping down the dose of ICS resulted in no clear benefit or harm
with respect to SAEs (OR 0.60, 95% CI 0.11 to 3.33; n = 569
participants; two studies; I2 = 35%; Analysis 2.4; Figure 7). For
people who stepped down their dose of ICS (versus those with no
change in ICS dose), we estimated that 13 fewer people per 1000
would have an SAE, but the confidence intervals ranged from 31
fewer to 74 more people per 1000. We rated the quality of the
evidence as low after downgrading once for risk of bias (selective
reporting) and once for imprecision (confidence intervals include
null effect and appreciable benefit (RR 0.75) or harm (RR 1.25)).
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Figure 7. Forest plot of comparison: 2 ICS dose reduction versus no change in ICS dose (concomitant
LABA), outcome: 2.4 All-cause SAEs.
Steroid-related AEs
ICS stepdown, no concomitant LABA
Stepping down the dose of ICS resulted in no clear benefit or harm
with respect to steroid-relatedAEs (OR0.76, 95%CI0.16 to 3.54;
n = 261 participants; two studies; I2 = 0%; Analysis 1.4; Figure 8).
For people who stepped down their dose of ICS (versus those with
no change in ICS dose), we estimated that eight fewer people per
1000 would have a steroid-related AE, but confidence intervals
ranged from 26 fewer to 69 more people per 1000. We rated the
quality of the evidence as very low after downgrading once for risk
of bias (selective reporting), once for indirectness (representative of
specialist centres) and once for imprecision (confidence intervals
include the null effect and appreciable benefit (RR 0.75) or harm
(RR 1.25)).
Figure 8. Forest plot of comparison: 1 ICS dose reduction versus no change in ICS dose (no concomitant
LABA), outcome: 1.4 Steroid-related AEs.
ICS stepdown, concomitant LABA
No included studies reported data for steroid-related AEs.
Secondary outcomes
Health-related quality of life
ICS stepdown, no concomitant LABA
There was a statistically significant difference in health-related
quality of life (change from baseline) between groups as measured
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by the Asthma Quality of Life Questionnaire (change from base-
line: MD -0.21, 95% CI -0.33 to -0.09; n = 554 participants,
one study; scale 0 (worst) to 7 (best); Analysis 1.5). However, the
mean difference and 95% confidence limits were below the mini-
mal clinically important difference (MCID) of 0.5, indicating no
clinically relevant difference between groups. We rated the quality
of the evidence as very low after downgrading twice for risk of bias
(selective reporting and lack of blinding for a subjective outcome
measure) and once for indirectness (single study representative of
a single setting and drug regimen).
ICS stepdown, concomitant LABA
Stepping down the dose of ICS resulted in no benefit or harmwith
respect to health-related quality of life as measured by St George’s
Respiratory Scale (change from baseline: MD 0.13, 95% CI -2.80
to 3.06; n = 229 participants, one study; scale 0 to 100 (greatest
impact of chest disease on life); Analysis 2.6) or the EuroQoL
(change from baseline: MD 2.32, 95% CI -1.64 to 6.28; n = 219
participants, one study; scale 0 to 100 (best imaginable health
state); Analysis 2.5). With regards to the St George’s Respiratory
Scale, the mean difference and 95% confidence limits were below
the MCID of 4 units, indicating no clinically relevant difference
between groups. We rated the quality of the evidence as low after
downgrading once for risk of bias (selective reporting) and once
for indirectness (single study representative of a single setting and
drug regimen).
Lung function
ICS stepdown, no concomitant LABA
Stepping down the dose of ICS resulted in no benefit or harm
with respect to lung function. There was no statistically significant
change in percent predicted FEV1 (MD -0.02, 95% CI -0.12 to
0.08; n = 261 participants, two studies; I2 = 0%; Analysis 1.7;
Figure 9) nor in morning PEFR (MD -5.98 L/min, 95% CI -
19.47 to 7.51; n = 875 participants, three studies; I2 = 0%; Analysis
1.6; Figure 10). We rated the quality of the evidence as low after
downgrading once for risk of bias (selective reporting) and once
for imprecision (confidence intervals include the null effect and
appreciable benefit (RR 0.75) or harm (RR 1.25)).
Figure 9. Forest plot of comparison: 1 ICS dose reduction versus no change in ICS dose (no concomitant
LABA), outcome: 1.7 Lung function, FEV1 (L).
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Figure 10. Forest plot of comparison: 1 ICS dose reduction versus no change in ICS dose (no concomitant
LABA), outcome: 1.6 Lung function, PEFR morning (L/min).
ICS stepdown, concomitant LABA
Stepping down the dose of ICS resulted in no benefit or harm
with respect to lung function. There was no statistically signifi-
cant between-group differences for change in percent predicted
FEV1 from baseline (MD -2.45, 95% CI -8.88 to 3.98; n = 14
participants, one study; Analysis 2.8) nor for change from baseline
in morning PEFR (MD -4.54, 95% CI -12.08 to 3.00; n = 310
participants, one study; Analysis 2.7). We rated the quality of the
evidence as very low after downgrading once for risk of bias (selec-
tive reporting), once for indirectness (single study representative
of a single setting and drug regimen) and once for imprecision
(wide CI).
Exacerbations requiring hospitalisation
ICS stepdown, no concomitant LABA
No studies reported the number of participants requiring hospi-
talisation.
ICS stepdown, concomitant LABA
Stepping down the dose of ICS resulted in no clear benefit or harm
with respect to exacerbations requiring hospitalisation (OR 4.06,
95% CI 0.45 to 36.86; n = 569 participants, two studies; I2 = 0%;
Analysis 2.9; Figure 11). For people who stepped down their dose
of ICS (versus thosewith no change in ICSdose), we estimated that
10 more people per 1000 would have an exacerbation requiring
hospitalisation, but the confidence intervals ranged from 2 fewer
to 112 more people per 1000. We rated the quality of the evidence
as low after downgrading once for risk of bias (selective reporting)
and once for imprecision (wide CI).
Figure 11. Forest plot of comparison: 2 ICS dose reduction versus no change in ICS dose (concomitant
LABA), outcome: 2.9 Exacerbation requiring hospitalisation.
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Exacerbations requiring an emergency department visit
ICS stepdown, no concomitant LABA
No studies reported the number of participants requiring an emer-
gency department visit.
ICS stepdown, concomitant LABA
Stepping down the dose of ICS resulted in no clear benefit or harm
with respect to exacerbations requiring an emergency department
visit (OR 2.00, 95% CI 0.18 to 22.33; n = 259 participants, one
study; Analysis 2.10). For people who stepped down their dose of
ICS (versus those with no change in ICS dose), we estimated that
7 more people per 1000 would have an exacerbation requiring
an emergency department visit, but confidence intervals ranged
from 7 fewer to 141 more people per 1000. We rated the quality
of the evidence as very low after downgrading once for risk of
bias (selective reporting), once for imprecision (wide CI) and once
for indirectness (single study representative of a single setting and
drug regimen).
Mortality
ICS stepdown, no concomitant LABA
No studies reported mortality data.
ICS stepdown, concomitant LABA
Stepping down the dose of ICS resulted in no clear benefit or harm
in terms of mortality; the single study reporting data (N = 310
participants; Analysis 2.11) reported no deaths in either group.
We rated the quality of the evidence as very low after downgrading
once for risk of bias (selective reporting), once for indirectness
(single study representative of a single setting and drug regimen)
and once for imprecision (no events reported).
Subgroup analyses
Magnitude of dose reduction
Review authors did not perform this prespecified subgroup anal-
ysis for either comparison because all of the included studies rep-
resented a 50% to 60% reduction in ICS dose.
Separate ICS/LABA inhalers versus combination ICS/LABA
inhaler
This was relevant only to the second comparison (participants who
were permitted to receive a concomitant LABA).
For exacerbations requiring oral corticosteroids, the use of indi-
vidual ICS and LABA inhalers (Hawkins 2003) versus a combined
inhaler (Godard 2008) did not appear to influence the overall
OR (1.31, 95% CI 0.82 to 2.08) because results of the two con-
tributing studies were comparable (OR 1.29, 95%CI 0.75 to 2.23
(Hawkins 2003) and OR 1.34, 95% CI 0.55 to 3.28 (Godard
2008), respectively).
We could not perform a subgroup analysis for asthma control
as only one study contributed data to each measure of asthma
control (short asthmamorbidity score (Hawkins 2003) and asthma
severity questionnaire (Juniper 1991)).
Sensitivity analyses
It was not possible for review authors to conduct the planned sen-
sitivity analyses because of the paucity of included studies con-
tributing to each outcome examined.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
ICS dose reduction compared with no change in ICS dose (concomitant LABA) for adults with asthma
Patient or population: adults with asthma
Setting: primary and secondary care
Intervention: ICS dose reduct ion
Comparison: no change in ICS dose (concomitant LABA)




Quality of the evidence
(GRADE)
Comments
Risk with no change in
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Follow-up: 12 months
Score 0-100. 100 =
greatest impact of
chest disease on lif e;
MCID is 4 units
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No clear benef it or
harm of stepping down
the dose of ICS with
respect to exacerba-
t ions requiring hospital-
isat ion (low-quality evi-
dence)
Lung funct ion, reduc-
t ion in FEV1 (% pre-
dicted, change f rom
baseline)
Follow-up: 3 months
Mean change f rom
baseline in % predicted
FEV1 was -0.75%.
MD 2.45 lower






No clear benef it or harm
of stepping down the
dose of ICS with re-
spect to lung funct ion
(very low-quality evi-
dence)
* Risk in the intervention group (and its 95% conf idence interval) is based on assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
aThe quality of the evidence was downgraded once for risk of bias (select ive report ing) and once for imprecision (conf idence intervals include null ef fect and appreciable
benef it or harm)
bThe quality of the evidence was downgraded once for risk of bias (select ive report ing) and once for indirectness (single study representat ive of one sett ing and drug regimen)
cNote that study authors reported the change to the lowest SGRQ score during follow-up
dThe quality of the evidence was downgraded once for risk of bias (select ive report ing) and once for imprecision (conf idence intervals include null ef fect and appreciable
benef it or harm)
eThe quality of the evidence was downgraded once for risk of bias (select ive report ing), once for indirectness (single study representat ive of one sett ing or drug regimen) and
once for imprecision (wide CI)
AE, adverse event; CI, conf idence interval; FEV1, f orced expiratory volume in one second; GRADE, Grades of Recommendation, Assessment, Development and Evaluat ion;
HRQoL, health-related quality of lif e; ICS, inhaled cort icosteroid; LABA, long-act ing beta agonist ; MCID, minimum clinically important dif f erence; MD, mean dif ference; OCS,








































































































GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect









































































































D I S C U S S I O N
Summary of main results
We included six studies, which randomised a total of 1654 par-
ticipants (inhaled corticosteroid (ICS) dose reduction, no con-
comitant long-acting beta agonist (LABA): n = 892 participants,
three randomised controlled trials (RCTs); ICS dose reduction,
concomitant LABA: n = 762, three RCTs). All included studies
were RCTs with a parallel design that compared a fixed dose of
ICS with a 50% to 60% reduction in the dose of ICS among
adult participants with well-controlled asthma. The duration of
treatment ranged from 12 to 52 weeks (mean duration 21 weeks;
median duration 14 weeks). Two studies were performed in the
setting of primary care, two were performed in the secondary care
setting and two provided no information on setting.
Meta-analysis was hampered by the small number of studies
that contributed to each comparison, combined with differences
among outcomes reported in the included studies. However, a low
level of heterogeneity was observed in the meta-analyses that were
performed. We found no statistically significant differences be-
tween groups (step-down of ICS vs no change in ICS) with respect
to any of the primary or secondary outcomes considered in this
review and thus were unable to determine whether stepping down
the dose of ICS in adults with asthma (comparedwithmaintaining
the previous dose of ICS) confers overall benefit. On one hand, we
did not identify a statistically significant between-group difference
for measures of effectiveness such as asthma control, lung function
or the number of participants experiencing exacerbations, which
would support the guideline-recommended use of an ICS dose
reduction for patients with well-controlled asthma. However, we
noted a numerical trend towards a greater number of participants
experiencing exacerbations, and we observed no benefit in terms
of other safety outcomes. Moreover, we rated the quality of the
evidence as generally low or very low, which means that we cannot
be confident in the effect estimates (see below). Finally, whether
concomitant treatment with a LABA influences the benefit/harm
ratio for stepping down ICS remains unclear.
Overall completeness and applicability of
evidence
Two of the included studies were performed in the primary care
setting, two in the secondary care setting and in two cases the set-
ting was not reported. Each comparison (± LABA) included one
study in each of these three categories (primary care, secondary
care, not stated); however, owing to the small number of stud-
ies contributing to each outcome, some outcomes may have been
more representative of a particular setting.When this was the case,
we accounted for this factor by downgrading the quality of the
evidence for indirectness. Furthermore, single studies (represen-
tative of a single regimen or treatment duration) contributed to
several of the outcomes, and most of the meta-analyses comprised
only two studies. Therefore, our results may be relevant to the par-
ticular treatment regimens represented in the individual studies.
Finally, our results are relevant only to adult patients. It is possible
that potential harms due to systemic effects associated with long-
term ICS use might be more relevant to children. To examine this,
we would need to consider including paediatric studies in future
iterations of this review, or in a separate review.
One of the concerns associated with stepping down the dose of
ICS in patients with well-controlled asthma is possible slow deteri-
oration in asthma control over time as bronchial hyper-responsive-
ness slowly returns. Moreover, long-term exposure to steroids may
result in the development of systemic side effects such as loss of
bone density in adults and growth retardation in children (Colice
2006; Lipworth 1999; SIGN/BTS 2016). The mean duration of
the included studies was 21 weeks (median duration 14 weeks),
which is potentially insufficient for detecting long-term deterio-
ration in asthma control/lung function or for adequately assessing
long-term safety outcomes.
Quality of the evidence
Few relevant studies met the prespecified criteria for inclusion; this
fact, combined with the use of varied outcome measures across in-
cluded studies, limited the number of meta-analyses that we could
perform. In terms of risk of bias, the included studies were gener-
ally of moderate quality, although selective reporting introduced
risk of bias in five out of six included studies. Furthermore, it was
not clear whether adequate methods of randomisation sequence
generation or concealment of allocation were used in all but one
study.
We assessed the quality of evidence in this review using GRADE
(Higgins 2011) and GRADEpro software; our findings in the
’Summary of findings tables’. Summary of findings for the main
comparison presents our findings for the first comparison (step-
ping down ICS vs no change in ICS, in patients not receiving
a concomitant LABA), and Summary of findings 2 presents our
findings for the second comparison (stepping down ICS vs no
change in ICS, in patients receiving a concomitant LABA). In
summary, for both comparisons, we assessed the quality of the
synthesised evidence as low or very low for most outcomes because
of risk of bias (principally, selective reporting), imprecision (few
events in a small number of studies, or wide confidence intervals)
and indirectness (single studies representative of a single setting or
drug regimen). Based on the quality of the evidence, we cannot
be confident about the effect estimates presented in this review.
Potential biases in the review process
We followed standard procedures as described in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011)
to minimise bias in the review process. With regard to the search
process, the Cochrane Airways Group Information Specialist de-
signed and conducted the main electronic search, two review au-
thors independently sifted the search results and two review au-
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thors (one with expert clinical knowledge) reviewed the full-text
results. Consistent with Cochrane methods, we excluded no trials
on the basis of language, publication status or outcomes reported,
so we are confident that we identified all potentially relevant evi-
dence from RCTs. In terms of our findings and conclusions, two
review authors independently performed all steps in the review
process for which a subjective decision was required (e.g. selection
of studies, extraction of data, assessment of risk of bias, assessment
of the overall quality of evidence using GRADE), and, if necessary,
a third review author assisted in resolving disagreements. Finally,
this review has undergone editorial and peer review such that the
opinion of independent external experts has been considered. To-
gether, these factors should ensure that our conclusions fairly rep-
resent the results synthesised during the review process.
Agreements and disagreements with other
studies or reviews
Our findings agree well with those of a systematic review
(Gionfriddo 2015) that examined the evidence for stepping down
the dose of ICS from a scheduled regimen to an as-needed basis.
Those review authors found insufficient evidence to associate step-
ping down ICS dose with an effect on the number of asthma exac-
erbations. In contrast, the authors found some evidence for fewer
symptom-free days in patients who used an ICS on an as-needed
basis. In another systematic review, Hagan and colleagues simi-
larly found that asthma exacerbations were statistically no more
likely among individuals who reduced ICS than among those who
maintained their ICS dose (Hagan 2014). The Hagan review in-
cluded studies of both adults and children and permitted step-
down to ICS on an as-needed basis. Nevertheless, their findings
are consistent with those of our review.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The effect of reducing ICS dose, in the presence or absence of a
LABA, on exacerbations and disease control in asthma remains
unknown. In addition,whether this strategy impacts quality of life,
hospitalisations and adverse events (steroid related or otherwise)
is unclear.
Implications for research
In light of considerable uncertainty around effect estimates, in par-
ticular for outcomes related to long-term safety, additional well-
designed RCTs are required to examine safety and effectiveness in
patients who step down their dose of ICS compared with those
who maintain their existing dose. It would be prudent for fu-
ture trials to use validated measures to examine asthma control
(e.g. Asthma Control Score) and health-related quality of life (e.g.
AsthmaQuality of LifeQuestionnaire). Future trials ideally should
last longer than six months (substantially longer periods would
be beneficial), first, to permit adequate monitoring of safety out-
comes, in particular, of potential systemic effects associated with
long-term use of ICS, and second, to ensure that slow deteriora-
tion of asthma control/lung function does not occur over time.
Measurement of airway hyper-responsiveness or airway inflamma-
tion at baseline and during follow-up may serve to explain why
the condition of some patients deteriorates, and others maintain
control on lower doses.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Godard 2008
Methods Study design: randomised controlled trial
Total duration of study: 24 weeks.
’Run-in’ period: 8 weeks. All participants received salmeterol/fluticasone propionate
combination (SFC) at a dose of 50/250 µg twice daily
Number of study centres and locations: 124 centres (no locations specified)
Study setting: not stated
Date of study: not stated
Participants Enrolled (N): 603
Randomised (n): 475 (SFC 50/250, n = 159; SFC 50/100, n = 157; FP 250, n = 159)
Analysed (n): 464 (SFC 50/250, n = 154; SFC 50/100, n = 156; FP 250, n = 154)
Withdrawals (n): 63
Median age (range), years: SFC 50/250, 46.5 (18-81); SFC 50/100, 43.0 (18-75); FP
250 42.0 (18-77)
Age range, years: 18-81
Gender (% female): SFC 50/250, 48.1; SFC 50/100, 46.2; FP 250 51.3
Severity of condition:well controlled on step 2 or 3.Mean%predicted prebronchodila-
tor FEV1 (SD) as follows: SFC 50/250, 87.8 (18.2); SFC 50/100, 91.2 (17.8); FP 250,
90.8 (17.2)
Diagnostic criteria: Asthma control was assessed using the GOAL definitions of ’well
controlled’ and ’total control’
Baseline lung function (mean morning PEF (SD), L/min): SFC 50/250, 465.6 (113.
2); SFC 50/100, 467.9 (111.2); FP 250, 463.7 (105.1)
Smoking history, % smokers or ex-smokers: SFC 50/250, 24.7; SFC 50/100, 21.3;
FP 250, 16.2
Inclusion criteria: aged ≥18 years; documented history of asthma (≥ 6 months) well
controlled with current treatment (ICS at a dose of CFC beclomethasone dipropionate
or equivalent and a long-acting beta2-agonist at recommended dose) at a stable dose
for ≥ 4 weeks before initial clinic visit (V1); respiratory tract infection, with acute
exacerbation requiring emergency department treatment/hospitalisation or use of oral/
parenteral steroids, within 4 weeks of V1; any change in asthma maintenance treatment
within 4 weeks
Exclusion criteria: smoking history ≥ 10 pack-years; respiratory tract infection
Details of criteria for stepping down treatment: All participants received SFC 50/250
µg twice daily and were randomised to remain on SFC 50/250 or move to 1 of the 2
step-down treatment arms if their asthma was assessed as ’well controlled’ over the last 2
weeks of the run-in period; asthma control was assessed according to GOAL definitions
(see Bateman 2004).
Interventions Intervention 1: SFC 50/100 µg twice daily
Intervention 2: FP 250 µg twice daily (not relevant to review)
Comparison: SFC 50/250 µg twice daily
Concomitant medications: Short-acting bronchodilators (previously used as rescue
medication) and antihistamines were permitted, provided they had been used for at least
4 weeks
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Godard 2008 (Continued)
Excluded medications: All previous asthma medications were discontinued at entry
into the run-in period, except short-acting bronchodilators (previously used as rescue
medication) and antihistamines, provided they had been used for at least 4 weeks
Outcomes Primary outcomes:mean morning PEF over the first 12 weeks of randomised treatment
Secondary outcomes: mean morning PEF over the last 12 weeks of randomised treat-
ment; daily symptoms; use of short-acting bronchodilator as rescue medication; FEV1;
asthma control based on GOAL definitions of total control and ’well-controlled’ (see
Bateman 2004)
Notes Funding for trial: not stated
Notable conflicts of interest of trial authors: Three of the trial authors had received
sponsorship and had attended advisory boards for various pharmaceutical companies,
including AstraZeneca, GlaxoSmithKline and Boehringer-Ingelheim; 3 authors are em-
ployees of GlaxoSmithKline
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information provided
Allocation concealment (selection bias) Unclear risk Insufficient information provided
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study reported as double blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Study reported as double blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data provided for all randomised individ-
uals. We note that study authors reported
lung function results only for the per-pro-
tocol population, whereas they reported all
other outcomes for the intent-to-treat pop-
ulation
Selective reporting (reporting bias) High risk Study authors reported the primary out-
come for the per-protocol data set on the
basis that this is a non-inferiority study.
Furthermore, the primary outcome con-
siders lung function only over the first 12
weeks of treatment; a secondary outcome
assessed lung function in the full analysis
set but considered only the second12weeks
of treatment. All in all, findings were quite
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confusing and inconsistent. This trial was
not reported as registered, and we cannot
source a protocol
Other bias High risk The protocol suggests that only partici-
pants whose condition was well controlled
within the last 2 weeks of the run-in pe-
riod would go on to randomisation; how-
ever, it appears that a relatively high propor-
tion of participants whose asthma was not
controlled were included in the full anal-
ysis set. Results of this study are not well
reported, and as the study does not appear
to have been prospectively registered, and
a protocol was not cited, it is difficult to as-
certain whether selective outcome report-
ing occurred. Study sponsorship is not re-
ported, although several authorsworked for
GSK. Key exclusion criteria of poor con-
trol according to ACQ were not defined or
reported. A large proportion of poorly con-
trolled randomised participants were not
included in the primary outcome analysis
(but were included in the secondary out-
come analysis). Reporting was confusing
Gunn 1997
Methods Study design: randomised controlled trial, multi-centre, open label
Total duration of study: 2-week run-in period; 12-week treatment period
’Run-in’ period: 2-week run in period, during which participants remained on their
existing doses of ICS (’high-dose’ budesonide 400 µg twice daily, beclomethasone 400
µg twice daily or beclomethasone 500 µg twice daily via a pMDI with a spacer; or ’low-
dose’ budesonide or beclomethasone 200 µg twice daily)
Number of study centres and locations: UK
Study setting: primary care
Withdrawals: 147/631 (23%) randomised participants withdrew during the treatment
period
Date of study: not stated
Participants N: 631 patients were randomised after a 2-week run-in period.
Mean age (range), years: budesonide OD: 44.1 (16.5-80.2); budesonide BID: 45.7
(16.7-77.0); no ICS dose change: 40.9 (16.2-80.2)
Gender M/F, n: budesonide OD: 100/128; budesonide BID: 90/101; no ICS dose
change: 100/112
Severity of condition: baseline mean morning PEFR (SD), L/min: controlled on step
2. Budesonide OD: 437.2 (106.5); budesonide BID: 447.4 (111.3); no ICS dose change:
445.8 (100.9)
Diagnostic criteria: mild, well controlled
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Baseline lung function - mean morning PEFR (SD), L/min: budesonide OD: 437.2
(106.5); budesonide BID: 447.4 (111.3); no ICS dose change: 445.8 (100.9)
Smoking history: not stated
Inclusion criteria: aged≥ 16 years; documented diagnosis of asthma (currently stable);
asthma considered by physician to be well controlled (as per BTS guidelines); receiving
200 µg twice daily (low dose) or 400/500 µg twice daily (high dose) budesonide or
beclomethasone (via a pMDI ± spacer) for 6 months before entry; patients on the higher
dose of steroid were required to have used a large volume spacer for a minimum of 4
weeks before entry
Exclusion criteria: pregnant, at risk of pregnancy, breast feeding, brittle asthma, night
shift workers.Within 3months: any increase in total daily inhaled steroid dose; exacerba-
tion resulting in hospitalisation or requiring nebulisation, oral/injectable/rectal steroids,
beta blockers, sodium cromoglycate, sodium nedocromil, any unlicensed medication or
fluticasone propionate. Within 1 week before the study: Patients were not permitted to
have taken theophylline (or derivatives), any long-acting bronchodilators, ipratropium/
oxitropium bromide or ketotifen
Details of criteria for stepping-down treatment: Participants were eligible for ran-
domisation if their diary cards showed that they had no nocturnal wakening due to
asthma in the previous 7 nights, and if they fulfilled 3 of the following criteria:
asthma symptoms of no more than mild severity experienced on 3 or fewer days of the
previous 7 days; using ≤ 1 puff per day of inhaled bronchodilator on a maximum of 5
of the last 7 days; circadian variation in PEFR < 20% in the previous 7 days; morning
PEFR ≥ 80% or predicted or best (if this value was greater than predicted) on 5 of the
7 previous days
Interventions Intervention: Participants on an initial high dose of ICS (budesonide 400µg twice daily
or beclomethasone 400µg twice daily or beclomethasone 500µg twice daily delivered via
a pMDI and a spacer device) were randomised to receive budesonide 200 µg twice daily
via a turbuhaler or 400 µg once daily (i.e. both groups represent a halving of the initial
ICS dose). Participants on an initial low dose of ICS (budesonide or beclomethasone
200 µg twice daily) were randomised to receive budesonide 100 µg twice daily via a
turbuhaler or 200 µg once daily (i.e. both groups represent a halving of the initial ICS
dose)
Comparison: No change in initial dose of budesonide or beclomethasone.
Concomitant medications: Each patient was given terbutaline (Bricanyl) turbuhaler
500 µg prn for rescue mediation during the run-in and throughout the study
Excluded medications: See exclusion criteria.
Outcomes Primary outcomes: morning PEFR recorded by diary cards (recorded at baseline, and
at 4, 8 and 12 weeks)
Secondary outcomes: evening PEFR, proportion of symptom-free days/nights, propor-
tion of beta2-agonist-free days/nights, sleep disturbance (all recorded via diary cards)
quality of life (Juniper Asthma Quality of Life Questionnaire (Juniper 1993); PEFR
measured at clinic visits; asthma severity measured at clinic visits; asthma control)
Notes Funding for trial: not stated; likely Astra Pharmaceuticals
Notable conflicts of interest of trial authors: not stated. One study author was an
employee of Astra Pharmaceuticals
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Gunn 1997 (Continued)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information provided
Allocation concealment (selection bias) Unclear risk Insufficient information provided
Blinding of participants and personnel
(performance bias)
All outcomes
High risk The study was open label.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk The study was open label, and it does not
appear that outcome assessors were blinded
to treatment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Incomplete primary outcome data were re-
ported, but the number of participants for
whom data were missing was similar across
OD/BD/pMDI groups
Selective reporting (reporting bias) High risk No study protocol available. The data
for high-dose and low-dose groups were
pooled and were not presented individu-
ally. Study authors stated that separate data
were not presented individually because no
significant differences between the 2 dose
groups were found for any of the analyses
performed
Other bias Unclear risk Unclear risk of bias: This is a complicated
study, and some changes in inhaler device
appear to have occurred at the same time
as changes in dose. Participants entered the
run-in period on their existing dose of ICS
(’high’ or ’low’) and were later randomised
to remain on their existing dose, or step
down to half the dose in 1 of 2 different
formats (half the dose twice daily, or the
same dose but only once daily). No data
were reported for the run-in period
Unclear risk of bias: Funding for the study
is not reported. The paper has industry
authors, and the company manufactures
products that seem to match the products
reported upon. Funding for the study is not
declared, but one study author is employed
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Methods Study design: randomised controlled trial, double-blind, parallel group
Total duration of study: 1 year
’Run-in’ period: 1 month
Number of study centres and locations: general practices in Western and Central
Scotland
Study setting: primary care (general practice)
Withdrawals: 24/130 participants in the stepdown group and 22/129 in the control
group discontinued the intervention. Analyses were performed on all randomised par-
ticipants
Date of study: The study was performed between May 1999 and October 2001.
Participants N: 259 participants were randomised.
Mean age (SD), years: step-down 52.8, (14.5); control 55 (15.2)
Age range: 18-86 years
Gender (M/F), n: step-down, 54/76; control, 54/75
Severity of condition: controlled on high-dose ICS (at least 1000µg BDP) plus possibly
other drugs (steps 2-4)
Baseline lung function - % predicted pre-salbutamol FEV1 (SD), L/min: step-down,
80.3 (19.2); control, 80.1 (18.6)
Smoking history - current/former/never, n: step-down, 16/44/70; control, 17/49/63
Inclusion criteria: aged ≥ 18 years; diagnosis of asthma ≥ 1 year; treated with ≥ 800
µg inhaled BDP (or budesonide or fluticasone propionate at equivalent dosage)
Exclusion criteria: required oral corticosteroids or attended general practice or hospital
within 2 months; inability to use peak flow meter; treatment with immunosuppressive
drugs; serious illness; alcohol, substance or drug misuse; pregnancy; participation in
other research within the past 6 months
Details of criteria for stepping down treatment: stable asthma (i.e. good control)
assessed at end of run-in period and at 3, 6, 9 and 12 months. Good control was defined
as an asthma morbidity score ≤ 2, no visits to general practice or hospital since previous
visit and peak flow ≥ target flow on 8 of the previous 14 days; if peak flow data were
missing, the first two criteria were used
Interventions Intervention: step-down - 50% reduction in ICS dose
Comparison: no change in ICS dose
Concomitant medications: Reliever inhalers were permitted. 36.9% of the step-down
group and 30.2% of the control group were receiving a concomitant LABA
Excluded medications: immunosuppresive drugs
Outcomes Primary outcomes: proportion of participants experiencing an asthma exacerbation,
asthma control (short asthma morbidity score (Rimmington 1997); scores ranged from
0 (perfect control) to 8 (very poor control))
Secondary outcomes: adverse events, health-related quality of life (EuroQoL and St
George’s Respiratory Questionnaire), annual corticosteroid dose
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Hawkins 2003 (Continued)
Notes Funding for trial: NHS R&D Programme on Asthma Management
Notable conflicts of interest of trial authors: Study authors had received funding,
and various pharmaceutical companies including GlaxoSmithKline provided the study
inhalers
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Well-described randomisation with com-
puter-generated randomisation stratified
by centre
Allocation concealment (selection bias) Low risk Computer-allo-
cated randomisation sequence; randomisa-
tion code withheld from investigators until
study completion
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and personnel were blinded to
treatment allocation via use of identical in-
haler packs
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Randomisation code was maintained blind
until the end of the study
Incomplete outcome data (attrition bias)
All outcomes
Low risk Primary outcome data were reported for
all participants as intention to treat. Some
data for health status secondary outcome
measures were missing (not explained), but
the number of participants for whom data
were missing was similar in both treatment
groups. Lung function was not reported
during or at the end of the treatment pe-
riod
Selective reporting (reporting bias) High risk Protocol was not available. It is not clear
why study authors did not present lung
function as, according to the Methods sec-
tion, participants did monitor lung func-
tion for 2 weeks before each visit. Detailed
adverse event data were not presented
Other bias Low risk Study medication was provided by indus-
try, but study was funded by NHS R&D
programme on asthma development. No
industry was involved in authorship of the
paper
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Juniper 1991
Methods Study design: randomised controlled trial, double-blind, parallel group
Total duration of study: 3 months
’Run-in’ period: no run-in (this is a follow-up extension to a previous study)
Number of study centres and locations: Firestone Regional Chest and Allergy Clinic at
St Joseph’s Hospital and the McMaster University Medical Centre in Hamilton, Canada
Study setting: secondary care (asthma clinic)
Withdrawals: All 28 participants completed the study
Date of study: not reported
Participants N: 28. A subgroup of 14 participants were relevant to this review
Mean age: not reported. Mean age in parent study was ~ 42 years (Juniper 1990).
Age range: not reported
Gender: not reported
Severity of condition: controlled on step 2 (mild to moderate: approximately half of
participants were ’steroid dependent’)
Baseline lung function: Individual participant data were reported. At entry to initial
study, all participants had airway hyper-responsiveness to methacholine (PC20 < 8.0
mg/mL) and symptomatic asthma
Smoking history: not reported
Inclusion criteria and exclusion criteria: successful completion of previous study
Details of criteria for step-down treatment: not reported
Interventions Intervention: a halving of the budesonide dose in steroid-dependent participants (n =
6)
Comparison: no change in budesonide dose among steroid-dependent participants (n
= 8)
Concomitant medications: Bronchodilator medication was permitted (long-acting vs
short-acting not specified)
Excluded medications: not reported
Outcomes Primary outcomes: airway responsiveness to methacholine (measured with a standard-
ised tidal breathing protocol); clinical asthma severity (i.e. asthma control assessed via
asthma severity questionnaire). The questionnaire comprised 6 items: awakened at night
by symptoms; awakened in the morning by symptoms; limitation of normal daily activi-
ties; sputum; use of bronchodilator more than 4 times per day; FEV1 prebronchodilator
< 70% predicted (One point was scored for each of the first 5 items that had been pos-
itive on ≥ 1 day during the previous week; 1 point was scored for reduced spirometry;
therefore, the maximum asthma severity score (i.e. worst control) was 6)
Secondary outcomes: bronchodilator use; allergen exposure score; upper respiratory
tract infection score
Notes Funding for trial: Funding was not reported.
Notable conflicts of interest of trial authors: Conflicts of interest were not reported.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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Juniper 1991 (Continued)
Random sequence generation (selection
bias)
Unclear risk Insufficient information provided
Allocation concealment (selection bias) Unclear risk Insufficient information provided
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The study was reported as double-blind.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The study was reported as double-blind.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All 28 randomised participants completed
the study, and it appears that data were re-
ported for all 28 participants
Selective reporting (reporting bias) High risk Study authors state, “During analysis, it
was found that all the outcomes in the
two reduction groupswere very similar, and
also, the outcomes in the two groups in
whom steroids were not reduced were very
similar. Therefore, for simplicity, the data
have been combined and are presented as
two groups, reduced and maintained”
No protocol was available; no prespeci-
fied analysis plan was prepared. Group data
were combined as described above
Other bias Low risk None identified
Knox 2007
Methods Study design: randomised controlled, double-blind, double-dummy, parallel group
Total duration of study: 14 weeks
’Run-in’ period: 2 weeks
Number of study centres and locations: 16 centres (8 each in UK and Belgium)
Study setting: not stated
Withdrawals: 5 participants (CIC 160 µg, n = 4; FP 250 µg, n = 1)
Date of study: October 2004 to July 2005
Participants N: 111 randomised
Mean age, years: CIC 160 µg OD: 43; FP 250 µg BID: 46
Age range, years: 18-75
Gender M/F, n: CIC 160 µg OD: 28/30; FP 250 µg BID: 30/23
Severity of condition: controlled on step 2
Baseline lung function - mean (SD) FEV1, L: CIC 160 µg OD: 3.272 (0.869); FP
250 µg BID: 3.146 (0.823)
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Knox 2007 (Continued)
Smoking history - non-smoker/ex-smoker/current smoker, n: CIC 160 µg OD: 38/
18/2; FP 250 µg BID: 34/18/1
Inclusion criteria: male and female patients aged 17-75 years; diagnosis of asthma as
defined by American Thoracic Society guidelines for at least 6 months, but otherwise
in good health; FEV1 ≥ 90% of predicted; maintained asthma control over previous 3
months using fluticasone propionate 250µg twice daily, or equivalent, with short-acting
bronchodilator use as rescue medication only
Exclusion criteria: concomitant severe disease, such as a lower respiratory tract infection;
chronic obstructive pulmonary disease or other relevant lung diseases; more than 1
emergency care visit or hospitalisation due to asthma exacerbations in the previous year;
or clinically relevant abnormal laboratory values suggesting an
unknown disease. Other exclusion criteria were use of systemic glucocorticoids, long-
acting β2-agonists,
oral β2-agonists and sustained-release xanthines within 3 months before study entry;
pregnancy and breast-feeding among
female patients; and ex-smokers or current smokers with ≥ 10 pack-years
Details of criteria for step-down treatment: Participants were randomised to step-
down (for eligibility, see inclusion and exclusion criteria)
Interventions Intervention: ciclesonide 160 µg OD (i.e. ~ 50% reduction according to GINA 2016)
Comparison: fluticasone propionate 250 µg BID (i.e. no change)
Concomitant medications: short-acting bronchodilator used as rescue medication only
Excluded medications: See exclusion criteria.
Outcomes Primary outcomes: efficacy - percentage of days with asthma control (defined as days
without asthma symptoms and without rescue medication use); asthma symptom-free
days; rescue medication-free days; and nocturnal awakening-free days. Safety - adverse
events
Secondary outcomes: efficacy - FEV1; forced vital capacity (FVC); PEF from spirome-
try; PEF from participant diaries measured on a Mini-Wright PEF meter; asthma symp-
tom scores from participant diaries (sum scores based on a 9-point scale, with 0 indi-
cating no symptoms); use of rescue medication; number of participants with an asthma
exacerbation; and time to onset of the first asthma exacerbation. Safety - vital signs
(blood pressure and pulse rate); standard laboratory tests (including haematology, blood
chemistry and urinalysis); and number of participants with oral candidiasis
Notes Funding for trial: This study was funded and sponsored by ALTANA Pharma AG, a
member of the Nycomed Group
Notable conflicts of interest of trial authors: Editorial assistance for preparation of the
manuscript was provided by Nathan Price-Lloyd, PhD, Medicus International, which
was funded by ALTANA Pharma AG, a member of the Nycomed Group. Study authors
reported no conflicts of interest
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information provided
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Knox 2007 (Continued)
Allocation concealment (selection bias) Unclear risk Insufficient information provided
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The study was reported as double-blind,
double-dummy.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The study was reported as double-blind,
double-dummy.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intention-to-treat analyses were performed
for safety analyses and comprised all ran-
domised participants. Some data for lung
function analyses were missing, but only
from 3 participants in the step-down group
Selective reporting (reporting bias) Unclear risk Protocol was not available; however, the
range of outcomes seems fairly comprehen-
sive
Other bias Low risk None identified
Magnussen 2000
Methods Study design: randomised controlled, double-blind, double-dummy, parallel group
Total duration of study: 14 weeks
’Run-in’ period: 4 weeks
Number of study centres and locations: 18 pulmonology practices
Study setting: pulmonology outpatient practices
Withdrawals: none reported
Date of study: November 1996 to October 1997
Participants N: 150
Mean (SD) age, years: 400 µg/day BDP: 43 (15); 1000 µg/day BDP: 42 (15)
Age range: not reported
Gender - M/F, n: 400 µg/day BDP: 22/50; 1000 µg/day BDP: 30/48
Severity of condition: step 2
Baseline lung function - mean (SE) FEV1, L: 400 µg/day BDP: 2.77 (0.09); 1000
µg/day BDP: 2.85 (0.09)
Smoking history: not reported
Inclusion criteria and exclusion criteria, allowable range: age 18-75 years; use of
inhaled steroids for ≥ 3 months (BDP 1000 mg or BUD 800-1000 mg); use of β2-
agonists on demand (≥ 1 puffs/d); reversible airflow obstruction assessed within the last
2 years; change in FEV ≥ 12%; change in PEF ≥ 20%; bronchial hyper-responsiveness
to inhaled histamine (PC20 FEV1 ≥ 4 mg/mL); baseline FEV1 ≥ 60% of predicted;
variability of baseline FEV1 during run-in period ≤ 15%
Details of criteria for step-down treatment: Participants were randomised to step-
down (for eligibility, see inclusion and exclusion criteria)
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Magnussen 2000 (Continued)
Interventions Intervention: hydrofluoroalkane beclomethasone 400 µg/day (i.e. < 50% dose reduc-
tion)
Comparison: chlorofluorocarbon beclomethasone 1000 µg/day.
Concomitant medications: not reported; likely that use of short-acting bronchodilators
as rescue medication was permitted
Excluded medications: none specified
Outcomes Primary outcomes: Efficacy - morning peak flow; Safety - adverse events
Secondary outcomes: evening peak flow, FEV1, concentration of inhaled histamine
causing a 20% decline in FEV1, frequency of β2-agonist use, daily asthma symptom
score (0 represents no symptoms; 5 represents severe symptoms); and sleep disturbance
score. Safety - oropharyngeal candidiasis; reported hoarseness; clinical laboratory tests (i.
e. haematology, serum chemistry, urine analysis); and vital signs (i.e. sitting pulse rate,
blood pressure, ECG)
Notes Funding for trial: 3M Medica (Borken, Germany)
Notable conflicts of interest of trial authors: not reported; however, several study
authors were employees of 3M Medica
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information provided
Allocation concealment (selection bias) Unclear risk Insufficient information provided
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The study was reported as double-blind.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The study was reported as double-blind.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Outcome data appear complete. Data ap-
pear to be reported for all randomised par-
ticipants
Selective reporting (reporting bias) High risk Protocol was not available. Reporting of
safety results appears to be fairly selective
(SAEs not reported, details of individual
AEs not reported)
Other bias Low risk None identified
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Abbreviations: BDP, beclomethasone dipropionate; BID, twice daily; BTS, British Thoracic Society; CFC, chlorofluorocarbon; CIC,
ciclesonide; ECG, electrocardiogram; FEV1, forced expiratory volume in 1 second; FP, fluticasone propionate; FVC, forced vital
capacity; GOAL, Gaining Optimal Asthma Control study; ICS, inhaled corticosteroid; LABA, long-acting beta agonist; NHS,
National Health Service; OD, once daily; PC20, provocative concentration that produces a 20% reduction in FEV1 from baseline
value; PEF, peak expiratory flow; PEFR, peak expiratory flow rate; pMDI, pressurised metered-dose inhaler; QoL, quality of life;
R&D, research and development; SD, standard deviation; SE, standard error; SFC, salmeterol formoterol combination; UK, United
Kingdom.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Aalbers 2004 Wrong intervention
Adachi 2001 Wrong patient population
ALA 2007 Wrong intervention
Anonymous 1979 Wrong intervention
Baba 1999 Wrong study design
Baba 2000 Wrong intervention
Bateman 2005 Wrong comparator
Belda 2006 Wrong study design
Boulet 1990 Wrong route of administration
Brambilla 1994 Wrong comparator
Britton 1997 Wrong study design
Bruggenjurgen 2005 Wrong intervention
Busse 2003 Wrong study design
Campbell 1998 Wrong intervention
Casale 2003 Wrong intervention
Chanez 2001 Wrong intervention
Chiu 2011 Wrong intervention
Chung 2002 Wrong intervention
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(Continued)
Davies 1977 Wrong intervention
Dorinsky 2003 Wrong intervention
Fardon 2005 Wrong intervention
Fardon 2007 Wrong intervention
FitzGerald 2003 Wrong intervention
FitzGerald 2005 Wrong intervention
FLIQ96 2005 Wrong study design
Fowler 2002 Wrong intervention
Haggart 2004 Wrong intervention
Hamada 2008 Wrong study design
Kardos 2001 Wrong intervention
Kawagishi 2000 Wrong study design
Keonig 2004 Wrong intervention
Massanari 2008 Wrong intervention
McKinlay 2011 Wrong intervention
Mikloweit 2000 Wrong study design
Obase 2013 Wrong intervention
Paggiaro 2011 Wrong comparator
Reddel 2007 Wrong intervention
Rumbak 1998 Wrong intervention
Schmier 2003 Wrong route of administration
Shamsul 2007 Wrong intervention
Ställberg 2003 Wrong intervention
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D A T A A N D A N A L Y S E S
Comparison 1. ICS dose reduction versus no change in ICS dose (no concomitant LABA)




participants Statistical method Effect size
1 Exacerbation requiring OCS 2 261 Odds Ratio (M-H, Random, 95% CI) 1.86 [0.16, 21.09]
2 Asthma control 1 Mean Difference (IV, Random, 95% CI) Totals not selected
3 All-cause SAEs 2 742 Odds Ratio (M-H, Random, 95% CI) 1.24 [0.25, 6.25]
4 Steroid-related AEs 2 261 Odds Ratio (M-H, Random, 95% CI) 0.76 [0.16, 3.54]
5 Juniper AQLQ score (change
from baseline)
1 Mean Difference (IV, Random, 95% CI) Totals not selected
6 Lung function, PEFR morning
(L/min)
3 875 Mean Difference (IV, Random, 95% CI) -5.98 [-19.47, 7.51]
7 Lung function, FEV1 (L) 2 261 Mean Difference (IV, Random, 95% CI) -0.02 [-0.12, 0.08]
Comparison 2. ICS dose reduction versus no change in ICS dose (concomitant LABA)




participants Statistical method Effect size
1 Exacerbation requiring OCS 2 569 Odds Ratio (M-H, Random, 95% CI) 1.31 [0.82, 2.08]
2 Asthma control (short asthma
morbidity score), change from
baseline
1 Mean Difference (IV, Random, 95% CI) Totals not selected
3 Asthma control (Asthma Severity
Questionnaire)
1 Mean Difference (IV, Random, 95% CI) Totals not selected
4 All-cause SAEs 2 569 Odds Ratio (M-H, Random, 95% CI) 0.60 [0.11, 3.33]
5 EuroQoL score (change from
baseline)
1 Mean Difference (IV, Random, 95% CI) Totals not selected
6 St. George’s Respiratory Scale
score (change from baseline)
1 Mean Difference (IV, Random, 95% CI) Totals not selected
7 Lung function, PEFR morning
(L/min) (change from baseline)
1 Mean Difference (IV, Random, 95% CI) Totals not selected
8 Lung function, reduction in
FEV1 (% predicted, change
from baseline)
1 Mean Difference (IV, Random, 95% CI) Totals not selected
9 Exacerbation requiring
hospitalisation
2 569 Odds Ratio (M-H, Random, 95% CI) 4.06 [0.45, 36.86]
10 Exacerbation requiring ED visit 1 Odds Ratio (M-H, Random, 95% CI) Totals not selected
11 Mortality 1 310 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
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Analysis 1.1. Comparison 1 ICS dose reduction versus no change in ICS dose (no concomitant LABA),
Outcome 1 Exacerbation requiring OCS.
Review: Stepping down the dose of inhaled corticosteroids for adults with asthma
Comparison: 1 ICS dose reduction versus no change in ICS dose (no concomitant LABA)
Outcome: 1 Exacerbation requiring OCS
Study or subgroup ICS dose reduction
No change








Knox 2007 2/58 1/53 100.0 % 1.86 [ 0.16, 21.09 ]
Magnussen 2000 0/72 0/78 Not estimable
Total (95% CI) 130 131 100.0 % 1.86 [ 0.16, 21.09 ]
Total events: 2 (ICS dose reduction), 1 (No change in ICS dose)
Heterogeneity: not applicable
Test for overall effect: Z = 0.50 (P = 0.62)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Favours dose reduction Favours no change
Analysis 1.2. Comparison 1 ICS dose reduction versus no change in ICS dose (no concomitant LABA),
Outcome 2 Asthma control.
Review: Stepping down the dose of inhaled corticosteroids for adults with asthma
Comparison: 1 ICS dose reduction versus no change in ICS dose (no concomitant LABA)
Outcome: 2 Asthma control







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Magnussen 2000 72 1.57 (2.0365) 78 1.79 (3.0911) -0.22 [ -1.05, 0.61 ]
-4 -2 0 2 4
Favours dose reduction Favours no change
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Analysis 1.3. Comparison 1 ICS dose reduction versus no change in ICS dose (no concomitant LABA),
Outcome 3 All-cause SAEs.
Review: Stepping down the dose of inhaled corticosteroids for adults with asthma
Comparison: 1 ICS dose reduction versus no change in ICS dose (no concomitant LABA)
Outcome: 3 All-cause SAEs
Study or subgroup ICS dose reduction
No change








Gunn 1997 3/419 2/212 73.1 % 0.76 [ 0.13, 4.57 ]
Knox 2007 2/58 0/53 26.9 % 4.73 [ 0.22, 100.90 ]
Total (95% CI) 477 265 100.0 % 1.24 [ 0.25, 6.25 ]
Total events: 5 (ICS dose reduction), 2 (No change in ICS dose)
Heterogeneity: Tau2 = 0.09; Chi2 = 1.06, df = 1 (P = 0.30); I2 =5%
Test for overall effect: Z = 0.26 (P = 0.79)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours dose reduction Favours no change
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Analysis 1.4. Comparison 1 ICS dose reduction versus no change in ICS dose (no concomitant LABA),
Outcome 4 Steroid-related AEs.
Review: Stepping down the dose of inhaled corticosteroids for adults with asthma
Comparison: 1 ICS dose reduction versus no change in ICS dose (no concomitant LABA)
Outcome: 4 Steroid-related AEs
Study or subgroup ICS dose reduction
No change








Knox 2007 1/58 2/53 40.1 % 0.45 [ 0.04, 5.08 ]
Magnussen 2000 2/72 2/78 59.9 % 1.09 [ 0.15, 7.92 ]
Total (95% CI) 130 131 100.0 % 0.76 [ 0.16, 3.54 ]
Total events: 3 (ICS dose reduction), 4 (No change in ICS dose)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.31, df = 1 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 0.35 (P = 0.73)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours dose reduction Favours no change
Analysis 1.5. Comparison 1 ICS dose reduction versus no change in ICS dose (no concomitant LABA),
Outcome 5 Juniper AQLQ score (change from baseline).
Review: Stepping down the dose of inhaled corticosteroids for adults with asthma
Comparison: 1 ICS dose reduction versus no change in ICS dose (no concomitant LABA)
Outcome: 5 Juniper AQLQ score (change from baseline)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Gunn 1997 (1) 369 -0.1891 (0.7766) 185 0.02 (0.63) -0.21 [ -0.33, -0.09 ]
-1 -0.5 0 0.5 1
Favours no change Favours dose reduction
(1) Presented as mean change from baseline.
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Analysis 1.6. Comparison 1 ICS dose reduction versus no change in ICS dose (no concomitant LABA),
Outcome 6 Lung function, PEFR morning (L/min).
Review: Stepping down the dose of inhaled corticosteroids for adults with asthma
Comparison: 1 ICS dose reduction versus no change in ICS dose (no concomitant LABA)
Outcome: 6 Lung function, PEFR morning (L/min)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Gunn 1997 444.1133 (116.3194) 407 207 455.5 (111.8) 50.6 % -11.39 [ -30.35, 7.58 ]
Knox 2007 58 459.84 (69.4559) 53 458.33 (67.6322) 28.0 % 1.51 [ -24.01, 27.03 ]
Magnussen 2000 72 410 (84.8528) 78 413 (97.1494) 21.4 % -3.00 [ -32.14, 26.14 ]
Total (95% CI) 537 338 100.0 % -5.98 [ -19.47, 7.51 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.68, df = 2 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 0.87 (P = 0.38)
Test for subgroup differences: Not applicable
-20 -10 0 10 20
Favours no change Favours dose reduction
51Stepping down the dose of inhaled corticosteroids for adults with asthma (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.7. Comparison 1 ICS dose reduction versus no change in ICS dose (no concomitant LABA),
Outcome 7 Lung function, FEV1 (L).
Review: Stepping down the dose of inhaled corticosteroids for adults with asthma
Comparison: 1 ICS dose reduction versus no change in ICS dose (no concomitant LABA)
Outcome: 7 Lung function, FEV1 (L)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Knox 2007 58 3.132 (0.2894) 53 3.15 (0.2839) 85.9 % -0.02 [ -0.12, 0.09 ]
Magnussen 2000 72 2.75 (0.7637) 78 2.8 (0.8832) 14.1 % -0.05 [ -0.31, 0.21 ]
Total (95% CI) 130 131 100.0 % -0.02 [ -0.12, 0.08 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.05, df = 1 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 0.45 (P = 0.66)
Test for subgroup differences: Not applicable
-0.2 -0.1 0 0.1 0.2
Favours no change Favours dose reduction
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Analysis 2.1. Comparison 2 ICS dose reduction versus no change in ICS dose (concomitant LABA),
Outcome 1 Exacerbation requiring OCS.
Review: Stepping down the dose of inhaled corticosteroids for adults with asthma
Comparison: 2 ICS dose reduction versus no change in ICS dose (concomitant LABA)
Outcome: 1 Exacerbation requiring OCS
Study or subgroup ICS dose reduction
No change








Godard 2008 12/156 9/154 26.9 % 1.34 [ 0.55, 3.28 ]
Hawkins 2003 40/130 33/129 73.1 % 1.29 [ 0.75, 2.23 ]
Total (95% CI) 286 283 100.0 % 1.31 [ 0.82, 2.08 ]
Total events: 52 (ICS dose reduction), 42 (No change in ICS dose)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 1.13 (P = 0.26)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
Favours dose reduction Favours no change
Analysis 2.2. Comparison 2 ICS dose reduction versus no change in ICS dose (concomitant LABA),
Outcome 2 Asthma control (short asthma morbidity score), change from baseline.
Review: Stepping down the dose of inhaled corticosteroids for adults with asthma
Comparison: 2 ICS dose reduction versus no change in ICS dose (concomitant LABA)
Outcome: 2 Asthma control (short asthma morbidity score), change from baseline







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Hawkins 2003 (1) 120 1.59 (1.96) 122 1.43 (2) 0.16 [ -0.34, 0.66 ]
-1 -0.5 0 0.5 1
Favours dose reduction Favours no change
(1) Change from baseline to worst reading during follow up
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Analysis 2.3. Comparison 2 ICS dose reduction versus no change in ICS dose (concomitant LABA),
Outcome 3 Asthma control (Asthma Severity Questionnaire).
Review: Stepping down the dose of inhaled corticosteroids for adults with asthma
Comparison: 2 ICS dose reduction versus no change in ICS dose (concomitant LABA)
Outcome: 3 Asthma control (Asthma Severity Questionnaire)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Juniper 1991 (1) 6 1.5 (1.64) 8 0.38 (0.52) 1.13 [ -0.24, 2.49 ]
-2 -1 0 1 2
Favours dose reduction Favours no change
(1) Scale 0-6; score 0 represents total control of asthma; score 6 represents least control of asthma
Analysis 2.4. Comparison 2 ICS dose reduction versus no change in ICS dose (concomitant LABA),
Outcome 4 All-cause SAEs.
Review: Stepping down the dose of inhaled corticosteroids for adults with asthma
Comparison: 2 ICS dose reduction versus no change in ICS dose (concomitant LABA)
Outcome: 4 All-cause SAEs
Study or subgroup ICS dose reduction
No change








Godard 2008 0/156 3/154 25.2 % 0.14 [ 0.01, 2.70 ]
Hawkins 2003 7/130 7/129 74.8 % 0.99 [ 0.34, 2.91 ]
Total (95% CI) 286 283 100.0 % 0.60 [ 0.11, 3.33 ]
Total events: 7 (ICS dose reduction), 10 (No change in ICS dose)
Heterogeneity: Tau2 = 0.72; Chi2 = 1.55, df = 1 (P = 0.21); I2 =35%
Test for overall effect: Z = 0.58 (P = 0.56)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Favours dose reduction Favours no change
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Analysis 2.5. Comparison 2 ICS dose reduction versus no change in ICS dose (concomitant LABA),
Outcome 5 EuroQoL score (change from baseline).
Review: Stepping down the dose of inhaled corticosteroids for adults with asthma
Comparison: 2 ICS dose reduction versus no change in ICS dose (concomitant LABA)
Outcome: 5 EuroQoL score (change from baseline)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Hawkins 2003 108 -7 (13.04) 111 -9.32 (16.69) 2.32 [ -1.64, 6.28 ]
-10 -5 0 5 10
Favours no change Favours dose reduction
Analysis 2.6. Comparison 2 ICS dose reduction versus no change in ICS dose (concomitant LABA),
Outcome 6 St. George’s Respiratory Scale score (change from baseline).
Review: Stepping down the dose of inhaled corticosteroids for adults with asthma
Comparison: 2 ICS dose reduction versus no change in ICS dose (concomitant LABA)
Outcome: 6 St. George’s Respiratory Scale score (change from baseline)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Hawkins 2003 110 7.53 (10.68) 119 7.4 (11.95) 0.13 [ -2.80, 3.06 ]
-4 -2 0 2 4
Favours dose reduction Favours no change
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Analysis 2.7. Comparison 2 ICS dose reduction versus no change in ICS dose (concomitant LABA),
Outcome 7 Lung function, PEFR morning (L/min) (change from baseline).
Review: Stepping down the dose of inhaled corticosteroids for adults with asthma
Comparison: 2 ICS dose reduction versus no change in ICS dose (concomitant LABA)
Outcome: 7 Lung function, PEFR morning (L/min) (change from baseline)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Godard 2008 156 1 (33.4732) 154 5.54 (34.2507) -4.54 [ -12.08, 3.00 ]
-10 -5 0 5 10
Favours no change Favours dose reduction
Analysis 2.8. Comparison 2 ICS dose reduction versus no change in ICS dose (concomitant LABA),
Outcome 8 Lung function, reduction in FEV1 (% predicted, change from baseline).
Review: Stepping down the dose of inhaled corticosteroids for adults with asthma
Comparison: 2 ICS dose reduction versus no change in ICS dose (concomitant LABA)
Outcome: 8 Lung function, reduction in FEV1 (% predicted, change from baseline)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Juniper 1991 6 -3.2 (5.5) 8 -0.75 (6.76) -2.45 [ -8.88, 3.98 ]
-20 -10 0 10 20
Favours maintenance Favours reduced dose
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Analysis 2.9. Comparison 2 ICS dose reduction versus no change in ICS dose (concomitant LABA),
Outcome 9 Exacerbation requiring hospitalisation.
Review: Stepping down the dose of inhaled corticosteroids for adults with asthma
Comparison: 2 ICS dose reduction versus no change in ICS dose (concomitant LABA)
Outcome: 9 Exacerbation requiring hospitalisation
Study or subgroup ICS dose reduction
No change








Godard 2008 0/156 0/154 Not estimable
Hawkins 2003 4/130 1/129 100.0 % 4.06 [ 0.45, 36.86 ]
Total (95% CI) 286 283 100.0 % 4.06 [ 0.45, 36.86 ]
Total events: 4 (ICS dose reduction), 1 (No change in ICS dose)
Heterogeneity: not applicable
Test for overall effect: Z = 1.25 (P = 0.21)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours dose reduction Favours no change
Analysis 2.10. Comparison 2 ICS dose reduction versus no change in ICS dose (concomitant LABA),
Outcome 10 Exacerbation requiring ED visit.
Review: Stepping down the dose of inhaled corticosteroids for adults with asthma
Comparison: 2 ICS dose reduction versus no change in ICS dose (concomitant LABA)
Outcome: 10 Exacerbation requiring ED visit
Study or subgroup ICS dose reduction
No change








Hawkins 2003 2/130 1/129 2.00 [ 0.18, 22.33 ]
0.01 0.1 1 10 100
Favours dose reduction Favours no change
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Analysis 2.11. Comparison 2 ICS dose reduction versus no change in ICS dose (concomitant LABA),
Outcome 11 Mortality.
Review: Stepping down the dose of inhaled corticosteroids for adults with asthma
Comparison: 2 ICS dose reduction versus no change in ICS dose (concomitant LABA)
Outcome: 11 Mortality
Study or subgroup ICS dose reduction
No change








Godard 2008 0/156 0/154 Not estimable
Total (95% CI) 156 154 Not estimable
Total events: 0 (ICS dose reduction), 0 (No change in ICS dose)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours [ICS dose reduction] Favours [No change]
A P P E N D I C E S
Appendix 1. Sources and search methods for the Cochrane Airways Group Specialised Register
Electronic searches: core databases
Database Frequency of search






58Stepping down the dose of inhaled corticosteroids for adults with asthma (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Handsearches: core respiratory conference abstracts
Conference Years searched
AmericanAcademyofAllergy, Asthma and Immunology (AAAAI) 2001 onwards
American Thoracic Society (ATS) 2001 onwards
Asia Pacific Society of Respirology (APSR) 2004 onwards
British Thoracic Society Winter Meeting (BTS) 2000 onwards
Chest Meeting 2003 onwards
European Respiratory Society (ERS) 1992, 1994, 2000 onwards
International PrimaryCareRespiratoryGroupCongress (IPCRG) 2002 onwards
Thoracic Society of Australia and New Zealand (TSANZ) 1999 onwards









8. (bronch$ adj3 spasm$).mp.
9. bronchoconstrict$.mp.
10. exp Bronchoconstriction/
11. (bronch$ adj3 constrict$).mp.
12. Bronchial Hyperreactivity/
13. Respiratory Hypersensitivity/
14. ((bronchial$ or respiratory or airway$ or lung$) adj3 (hypersensitiv$ or hyperreactiv$ or allerg$ or insufficiency)).mp.
15. ((dust or mite$) adj3 (allerg$ or hypersensitiv$)).mp.
16. or/1-15
Filter to identify RCTs
1. exp “clinical trial [publication type]”/
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11. 9 not (9 and 10)
12. 8 not 11
The MEDLINE strategy and the RCT filter are adapted to identify trials in other electronic databases.
Appendix 2. Search strategy to identify relevant trials from the Cochrane Airways Group
Specialised Register
#1 AST:MISC1
#2 MeSH DESCRIPTOR Asthma Explode All
#3 asthma*:ti,ab
#4 #1 or #2 or #3
#5 MeSH DESCRIPTOR Adrenal Cortex Hormones Explode All
#6 (steroid* or corticosteroid* or glucocorticosteroid* or glucocorticoid* or corticoid*) AND (inhal*)
#7 ICS:ti,ab,kw







#15 #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14
#16 step* NEAR3 down*
#17 (reduc* or decreas*) NEAR3 (dose* or treatment* or therap*)
#18 down* NEAR3 titrat*
#19 MeSH DESCRIPTOR Drug Administration Schedule Explode All
#20 #16 or #17 or #18 or #19
#21 #4 AND #15 AND #20
[Note: in search line #1, MISC1 denotes the field in which the reference has been coded for condition, in this case, asthma.]
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We used the mean difference instead of the standardised mean difference, as a combination of different scales would make clinical
interpretation of the effect measure difficult.
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